Comparative cost-effectiveness analysis of oral triptan therapy for migraine in four European countries

被引：0
|
作者：
Manuel Hens
Ana Villaverde-Hueso
Veronica Alonso
Ignacio Abaitua
Manuel Posada de la Paz
机构：
[1] Instituto de Salud Carlos III,Rare Diseases Research Institute
[2] Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER),undefined
来源：
The European Journal of Health Economics | 2014年 / 15卷
关键词：
Migraine; Therapy; Triptans; Cost-effectiveness; Health economics; Treatment; I10; I13; I18;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：433 / 437
页数：4
相关论文
共 50 条
  • [21] Optimizing HIV retesting during pregnancy and postpartum in four countries: a cost-effectiveness analysis
    Meisner, Julianne
    Roberts, D. Allen
    Rodriguez, Patricia
    Sharma, Monisha
    Owiredu, Morkor Newman
    Gomez, Bertha
    de Mello, Maeve B.
    Bobrik, Alexey
    Vodianyk, Arkadii
    Storey, Andrew
    Githuka, George
    Chidarikire, Thato
    Barnabas, Ruanne
    Farid, Shiza
    Essajee, Shaffiq
    Jamil, Muhammad S.
    Baggaley, Rachel
    Johnson, Cheryl
    Drake, Alison L.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24 (04)
  • [22] Treatment of migraine in Canada with naratriptan: A cost-effectiveness analysis
    Caro, JJ
    Getsios, D
    Raggio, G
    Caro, G
    Black, L
    HEADACHE, 2001, 41 (05): : 456 - 464
  • [23] Cost-Effectiveness of Prison System Development - Comparison of the European Countries
    Kruze, Elina
    Priede, Janis
    EUROPEAN INTEGRATION STUDIES, 2020, (14) : 69 - 79
  • [24] COST-EFFECTIVENESS OF ORAL TRIPTANS FOR ACUTE MIGRAINE: MIXED TREATMENT COMPARISON
    Asseburg, Christian
    Peura, Piia
    Oksanen, Tuija
    Turunen, Juha
    Purmonen, Timo
    Martikainen, Janne
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2012, 28 (04) : 382 - 389
  • [25] COST-EFFECTIVENESS ANALYSIS OF THE THERAPY OF ENDOMETRIOSIS
    Tuletova, A.
    Dochshanova, A.
    Skakova, R.
    VALUE IN HEALTH, 2014, 17 (07) : A511 - A511
  • [26] Cost-effectiveness analysis of fixed combination therapies Ganfort, Duotrav and Xalacom in European countries
    Hommer, A. B.
    Friis, M.
    Wickstrom, J.
    Poulsen, P. B.
    Walt, J. G.
    Buchholz, P.
    VALUE IN HEALTH, 2007, 10 (06) : A347 - A348
  • [27] Cost-effectiveness of rituximab therapy for rheumatoid arthritis: A Pan-European analysis
    Kielhorn, A
    Rubbert, A
    Porter, D
    De Vita, S
    Brown, B
    Aristides, M
    Aultman, R
    Jost, F
    VALUE IN HEALTH, 2006, 9 (03) : A27 - A27
  • [28] Cost-effectiveness analysis of patient self-testing therapy of oral anticoagulation
    Sutat Kantito
    Surasak Saokaew
    Sukit Yamwong
    Prin Vathesatogkit
    Wisuit Katekao
    Piyamitr Sritara
    Nathorn Chaiyakunapruk
    Journal of Thrombosis and Thrombolysis, 2018, 45 : 281 - 290
  • [29] Cost-effectiveness analysis of patient self-testing therapy of oral anticoagulation
    Kantito, Sutat
    Saokaew, Surasak
    Yamwong, Sukit
    Vathesatogkit, Prin
    Katekao, Wisuit
    Sritara, Piyamitr
    Chaiyakunapruk, Nathorn
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2018, 45 (02) : 281 - 290
  • [30] Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia
    Bewersdorf, Jan Philipp
    Patel, Kishan K.
    Huntington, Scott F.
    Zeidan, Amer M.
    BLOOD ADVANCES, 2021, 5 (22) : 4686 - 4690
12345